ProQR Therapeutics reports Q3 cash position of €106.9 million and initiates Phase 1 trial of AX-0810
ProQR Therapeutics NV reported a Q3 cash position of €106.9 million, down from €149.4 million at the end of 2024. The company used €39.4 million in operating activities in the first nine months of 2025, with R&D costs rising to €34.8 million. ProQR achieved $2.0 million in milestone payments from Eli Lilly and received CTA authorization for a Phase 1 trial of AX-0810, with initial data expected by year-end. The cash position is projected to last until mid-2027.
ProQR Therapeutics NV reported cash and cash equivalents of €106.9 million as of September 30, 2025, down from €149.4 million at December 31, 2024. Net cash used in operating activities during the first nine months of 2025 was €39.4 million, compared to €27.0 million for the same period in the previous year. Research and development costs were €34.8 million for the nine months ended September 30, 2025, up from €25.7 million in the prior year. General and administrative costs totaled €11.2 million, compared to €9.7 million in 2024. During this period, ProQR achieved milestones in its collaboration with Eli Lilly, resulting in $2.0 million (approximately €1.8 million) in milestone payments. The company received CTA authorization for its Phase 1 trial of lead program AX-0810 for cholestatic diseases, with initial safety, tolerability, and PK data expected by year-end and target engagement data anticipated in the first half of 2026. ProQR stated its cash position provides runway into mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137251-en) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
